Oxyphenbutazone

Research use only, not for human use.

Oxyphenbutazone is a non-selective COX inhibitor. Oxyphenbutazone is a phenylbutazone derivative.

Oxyphenbutazone is a Phenylbutazone (HY-B0230) metabolite, with anti-inflammatory effect. Oxyphenbutazone is an orally active non-selective COX inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.

Oxyphenbutazone enhances the anticancer efficiency of Methotrexate (MTX) (HY-14519) in Hep3B cells.Oxyphenbutazone (2.5-7.5 μM; 48 hours) co-treatment with (MTX, 0.25-1.0 μM) shows potential cytotoxicity against Hep3B cells.Oxyphenbutazone exhibits reparative effects in the hepatocytes.Cell Cytotoxicity Assay Cell Line:Hep3B cells Concentration:2.5 μM, 5 μM, 7.5 μM Incubation Time:48 hours Result:Enhanced the cytotoxicity of MTX.

Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.).Animal Model:Wistar strain albino male rats (5-6 weeks; 150-220 g) Dosage:70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week) Administration:PO; once a week; in two divided doses; for 13 weeks Result:Exerted potential anticancer activity in rats when co-treatment with MTX.

——

Chromatin/Epigenetic

COX

COX

——

——

129-20-4

324.37

C19H20N2O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (308.29 mM; Ultrasonic )

CCCCC1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years